178 related articles for article (PubMed ID: 14720204)
1. Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells.
Biasini E; Fioriti L; Ceglia I; Invernizzi R; Bertoli A; Chiesa R; Forloni G
J Neurochem; 2004 Feb; 88(3):545-53. PubMed ID: 14720204
[TBL] [Abstract][Full Text] [Related]
2. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
3. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
Petrucelli L; O'Farrell C; Lockhart PJ; Baptista M; Kehoe K; Vink L; Choi P; Wolozin B; Farrer M; Hardy J; Cookson MR
Neuron; 2002 Dec; 36(6):1007-19. PubMed ID: 12495618
[TBL] [Abstract][Full Text] [Related]
4. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.
Tanaka Y; Engelender S; Igarashi S; Rao RK; Wanner T; Tanzi RE; Sawa A; L Dawson V; Dawson TM; Ross CA
Hum Mol Genet; 2001 Apr; 10(9):919-26. PubMed ID: 11309365
[TBL] [Abstract][Full Text] [Related]
5. [Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease].
Corti O; Brice A
J Soc Biol; 2002; 196(1):95-10. PubMed ID: 12134640
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.
McLean PJ; Kawamata H; Hyman BT
Neuroscience; 2001; 104(3):901-12. PubMed ID: 11440819
[TBL] [Abstract][Full Text] [Related]
7. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.
Lee G; Junn E; Tanaka M; Kim YM; Mouradian MM
J Neurochem; 2002 Oct; 83(2):346-52. PubMed ID: 12423244
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
McNaught KS; Olanow CW
Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-proteasome system and Parkinson's diseases.
Betarbet R; Sherer TB; Greenamyre JT
Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
[TBL] [Abstract][Full Text] [Related]
10. Parkin accumulation in aggresomes due to proteasome impairment.
Junn E; Lee SS; Suhr UT; Mouradian MM
J Biol Chem; 2002 Dec; 277(49):47870-7. PubMed ID: 12364339
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways of neurodegeneration in Parkinson's disease.
Dawson TM; Dawson VL
Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells.
Ancolio K; Alves da Costa C; Uéda K; Checler F
Neurosci Lett; 2000 May; 285(2):79-82. PubMed ID: 10793231
[TBL] [Abstract][Full Text] [Related]
13. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.
Tofaris GK; Layfield R; Spillantini MG
FEBS Lett; 2001 Nov; 509(1):22-6. PubMed ID: 11734199
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of neurodegeneration in Parkinson's disease: clues from Mendelian syndromes.
Lim KL; Lim TM
IUBMB Life; 2003 Jun; 55(6):315-22. PubMed ID: 12938733
[TBL] [Abstract][Full Text] [Related]
15. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W; Lesuisse C; Xu Y; Troncoso JC; Price DL; Lee MK
J Neurosci; 2004 Aug; 24(33):7400-9. PubMed ID: 15317865
[TBL] [Abstract][Full Text] [Related]
16. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
Rideout HJ; Larsen KE; Sulzer D; Stefanis L
J Neurochem; 2001 Aug; 78(4):899-908. PubMed ID: 11520910
[TBL] [Abstract][Full Text] [Related]
17. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.
Sawada H; Kohno R; Kihara T; Izumi Y; Sakka N; Ibi M; Nakanishi M; Nakamizo T; Yamakawa K; Shibasaki H; Yamamoto N; Akaike A; Inden M; Kitamura Y; Taniguchi T; Shimohama S
J Biol Chem; 2004 Mar; 279(11):10710-9. PubMed ID: 14672949
[TBL] [Abstract][Full Text] [Related]
18. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.
Stefanis L; Larsen KE; Rideout HJ; Sulzer D; Greene LA
J Neurosci; 2001 Dec; 21(24):9549-60. PubMed ID: 11739566
[TBL] [Abstract][Full Text] [Related]
19. alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines.
Martìn-Clemente B; Alvarez-Castelao B; Mayo I; Sierra AB; Dìaz V; Milán M; Fariñas I; Gómez-Isla T; Ferrer I; Castaño JG
J Biol Chem; 2004 Dec; 279(51):52984-90. PubMed ID: 15466467
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Ardley HC; Scott GB; Rose SA; Tan NG; Markham AF; Robinson PA
Mol Biol Cell; 2003 Nov; 14(11):4541-56. PubMed ID: 12937272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
